P-Cure, Ltd has received a 510(k) letter from the U.S. Food and Drug Administration (FDA) permitting it to market its P-ARTIS CT scanner system, which is a computed tomography (CT) imaging system intended to scan patients while seated. The Northwestern Medicine Chicago Proton Center will be the first proton center in the U.S. to use P-Cure’s innovative imaging technology for patients being treated for lung cancer.
“This technology is an important addition to our proton offerings,” said William Hartsell, MD, radiation oncologist and Medical Director, Northwestern Medicine Chicago Proton Center. “We expect that imaging lung cancer patients in an upright position will allow us to more precisely target the tumor when we treat it with the proton beam.
Using a diagnostic CT scanning system, this new system will allow proton therapy treatment planning images to be taken with patients in a seated position. This system will allow for enhanced imaging of target tumors that will be treated with proton beams – which also occurs in the seated position. The seated position for imaging and treatment is expected to provide a greater degree of comfort for the patient during treatment and may decrease tumor motion making the proton treatments more precise.
“The P-Cure team is excited to work in collaboration with the Northwestern Medicine Chicago Proton Center, an internationally recognized center of excellence for cancer treatment. Our goal is to create more clinical flexibility for new and existing proton centers,” said Michael Marash, MD, Chief Executive Officer, P-Cure, Ltd.
“This technology is an important addition to our proton offerings,” said William Hartsell, MD, radiation oncologist and Medical Director, Northwestern Medicine Chicago Proton Center. “We expect that imaging lung cancer patients in an upright position will allow us to more precisely target the tumor when we treat it with the proton beam.
Using a diagnostic CT scanning system, this new system will allow proton therapy treatment planning images to be taken with patients in a seated position. This system will allow for enhanced imaging of target tumors that will be treated with proton beams – which also occurs in the seated position. The seated position for imaging and treatment is expected to provide a greater degree of comfort for the patient during treatment and may decrease tumor motion making the proton treatments more precise.
“The P-Cure team is excited to work in collaboration with the Northwestern Medicine Chicago Proton Center, an internationally recognized center of excellence for cancer treatment. Our goal is to create more clinical flexibility for new and existing proton centers,” said Michael Marash, MD, Chief Executive Officer, P-Cure, Ltd.